Dr. Harel is an accomplished executive with extensive experience in value creation for early-stage projects, including developing financing strategies and raising R&D funding. Between 2013 and 2019 she served as the acting CEO of GAVISH Bio-applications Ltd., the Technology Transfer, and commercialization arm of The Galilee Research Institute. While at the Institute, Dr. Harel co-founded and managed a technology accelerator within the institute leading to the establishment of several startup companies. She was the facilitator of several startups such as Immpact-Bio, Gentibio, and Projini. Dr. Harel served as a board member of the Israeli Technology Transfer organizations (ITTN), and was a board member of Immpact-Bio, which develops disruptive CAR-T therapies based on an invention by the co-inventor of CAR-T and among its shareholders are J&J, Takeda Ventures, Orbimed, and Novartis Venture Fund. Dr. Harel earned her Ph.D. degree in Biology from the Hebrew University of Jerusalem and was a postdoctoral fellow in the Cell Biology and Metabolism Branch at the NIH.